505082-83-7

Usage

Derivative of biphenyl

The compound is based on a biphenyl structure, which is a widely used building block in organic synthesis. This indicates that it can be further modified or used as a starting point for the synthesis of other compounds.

Presence of fluorine atoms

The addition of two fluorine atoms to the biphenyl structure can alter its physical and chemical properties. This modification can make the compound more suitable for various applications in the pharmaceutical and materials science industries.

Carboxylic acid group

The presence of a carboxylic acid group (-COOH) in the molecule makes it potentially useful for drug development and as a building block for organic synthesis. This functional group can participate in various chemical reactions and form different derivatives.

Reactivity

The specific properties and potential applications of 2',3-Difluoro-[1,1'-biphenyl]-4-carboxylic acid would depend on its reactivity with other molecules. This includes its ability to form salts, esters, and amides, as well as its participation in other chemical reactions.

Solubility

The solubility of the compound in various solvents, such as water, organic solvents, or both, can influence its potential applications. For example, good solubility in water may make it more suitable for pharmaceutical applications, while solubility in organic solvents may be beneficial for materials science applications.

Interactions with other molecules

The compound's ability to interact with other molecules, such as proteins, enzymes, or other biomolecules, can determine its potential use in drug development or as a building block for organic synthesis.

Potential applications

Due to its unique structure and properties, 2',3-Difluoro-[1,1'-biphenyl]-4-carboxylic acid has the potential to contribute to the advancement of diverse fields such as chemistry, medicine, and materials science. This includes its use in drug development, as a building block for organic synthesis, or in the creation of new materials with specific properties.

Upstream product

• 1993-03-9 o-fluorophenylboronic acid 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity relationship studies of L-amino alcohol derivatives as broad-spectrum antifungal agents

To discover broad spectrum antifungal agents, two strategies were applied, and a novel class of L-amino alcohol derivatives were designed and synthesized. 3-F substituted compounds 14i, 14n, 14s and 14v exhibited excellent antifungal activities with broad antifungal spectra against C. albicans and C. tropicalis, with MIC values in the range of 0.03–0.06 μg/mL, and against A. fumigatus and C. neoformans, with MIC values in the range of 1–2 μg/mL. Notably, Compounds 14i, 14n, 14s and 14v also displayed moderate activities against fluconazole-resistance strains 17# and CaR that were isolated from AIDS patients. Moreover, only compounds in the S-configuration showed antifungal activity. Preliminary mechanistic studies showed that the potent antifungal activity of compound 14v stemmed from inhibition of C. albicans CYP51. Compounds 14n and 14v were almost nontoxic to mammalian A549 cells, and their stability in human plasma was excellent.

Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents

To further explore the structure activity relationships (SARs) of our previously discovered antifungal lead compound (1), a series of biphenyl imidazole analogues were designed, synthesized and evaluated for their in vitro antifungal activity. Many of the

Rational development of 4-aminopyridyl-based inhibitors targeting trypanosoma cruzi CYP51 as anti-chagas agents

A new series of 4-aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) has been developed using structure-based drug design as well as structure-property relationship (SPR) analyses. The screening hit starting point, LP10 (KD ≤ 42 nM; EC50 = 0.65 μM), has been optimized to give the potential leads 14t, 27i, 27q, 27r, and 27t, which have low-nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts (EC50 = 14-18 nM for 27i and 27r). Many of the optimized compounds have improved microsome stability, and most are selective against human CYPs 1A2, 2D6, and 3A4 (50% inhibition at 1 μM). A rationale for the improvement in microsome stability and selectivity of inhibitors against human metabolic CYP enzymes is presented. In addition, the binding mode of 14t with the Trypanosoma brucei CYP51 (TbCYP51) orthologue has been characterized by X-ray structure analysis.

Amine Compounds

There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS

The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.

MUSCARINIC AGONISTS

The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.

MUSCARINIC AGONISTS

The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.